JP2004515232A - 修飾されたアルギニンデイミナーゼ - Google Patents

修飾されたアルギニンデイミナーゼ Download PDF

Info

Publication number
JP2004515232A
JP2004515232A JP2002546708A JP2002546708A JP2004515232A JP 2004515232 A JP2004515232 A JP 2004515232A JP 2002546708 A JP2002546708 A JP 2002546708A JP 2002546708 A JP2002546708 A JP 2002546708A JP 2004515232 A JP2004515232 A JP 2004515232A
Authority
JP
Japan
Prior art keywords
group
mycoplasma
arginine deiminase
microorganism
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002546708A
Other languages
English (en)
Japanese (ja)
Inventor
クラーク，マイク・エイ
Original Assignee
フエニツクス・フアーマコロジクス・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/723,546 external-priority patent/US6737259B1/en
Application filed by フエニツクス・フアーマコロジクス・インコーポレーテツド filed Critical フエニツクス・フアーマコロジクス・インコーポレーテツド
Publication of JP2004515232A publication Critical patent/JP2004515232A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2002546708A 2000-11-28 2001-09-19 修飾されたアルギニンデイミナーゼ Pending JP2004515232A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/723,546 US6737259B1 (en) 1997-05-12 2000-11-28 Modified arginine deiminase
PCT/US2001/029184 WO2002044360A2 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee

Publications (1)

Publication Number Publication Date
JP2004515232A true JP2004515232A (ja) 2004-05-27

Family

ID=24906720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002546708A Pending JP2004515232A (ja) 2000-11-28 2001-09-19 修飾されたアルギニンデイミナーゼ

Country Status (7)

Country Link
EP (1) EP1337630A2 (fr)
JP (1) JP2004515232A (fr)
KR (1) KR20040004449A (fr)
CN (1) CN1518595A (fr)
AU (1) AU2001289132A1 (fr)
CA (1) CA2430077A1 (fr)
WO (1) WO2002044360A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538761A (ja) * 2005-04-25 2008-11-06 エリテシュ ファルマ アルギニンデイミナーゼを含む赤血球

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
RU2335539C2 (ru) * 2002-06-20 2008-10-10 Байо-Кэнсер Тритмент Интернэшнл Лимитид Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
JP4733393B2 (ja) * 2002-11-18 2011-07-27 ポラリス・グループ インビボでウイルス複製を阻害する方法
WO2005107815A2 (fr) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Dérivés de polymères comprenant un point de ramification de type imide
WO2006015512A1 (fr) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Arginine déiminase modifiée
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN101812438B (zh) * 2010-03-25 2014-08-27 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
CN102703339B (zh) * 2011-08-29 2013-08-14 山东恩贝生物工程有限公司 高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
ES2828656T3 (es) 2012-04-04 2021-05-27 Polaris Group Composición que comprende arginina desiminasa pegilada
EP2968482B1 (fr) 2013-03-15 2020-05-06 TDW Group Arginine désiminase à réactivité croisée réduite envers les anticorps anti-adi-peg 20 pour le traitement du cancer
SG11201607736UA (en) * 2014-03-18 2016-10-28 Tdw Group Engineered chimeric pegylated adi and methods of use
ES2915382T3 (es) 2014-09-16 2022-06-22 Polaris Group Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer
ES2905716T3 (es) * 2016-09-29 2022-04-11 Meharry Medical College Péptidos derivados de la arginina deiminasa de S. cristatus como inhibidores bacterianos
EP3534963B1 (fr) * 2016-11-02 2024-04-17 Polaris Group Formulations d'arginine déiminase pegylée
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN106591270B (zh) * 2017-01-23 2018-09-21 江南大学 一株定点突变改造的基因工程精氨酸脱亚胺酶
JP2021505661A (ja) * 2017-11-30 2021-02-18 ジャズ ファーマシューティカルズ アイルランド リミテッド アスパラギナーゼを用いた治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3209338B2 (ja) * 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538761A (ja) * 2005-04-25 2008-11-06 エリテシュ ファルマ アルギニンデイミナーゼを含む赤血球

Also Published As

Publication number Publication date
WO2002044360A3 (fr) 2002-12-19
EP1337630A2 (fr) 2003-08-27
WO2002044360A2 (fr) 2002-06-06
KR20040004449A (ko) 2004-01-13
CN1518595A (zh) 2004-08-04
CA2430077A1 (fr) 2002-06-06
AU2001289132A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
JP4456184B2 (ja) 修飾されたアルギニンデイミナーゼ
JP5341945B2 (ja) 非免疫原性ポリマー結合体の調製のための凝集体非含有尿酸オキシダーゼ
JP2004515232A (ja) 修飾されたアルギニンデイミナーゼ
Pasut et al. Anti-cancer PEG-enzymes: 30 years old, but still a current approach
RU2349341C2 (ru) Конъюгаты peg-уратоксидазы, их использование, способ изолирования тетрамерной формы уриказы
US20090081180A1 (en) Antimicrobial polymer conjugates
Tsui et al. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)
TW202103730A (zh) 用於治療癌症之與adi-peg 20抗體具有降低之交叉反應性的精胺酸脫亞胺酶
JP2007516178A (ja) Ｐ．ｃａｒｉｎｉｉのリアーゼ処理